Page 7 - Downstream Processing News Today

/PRNewswire/ -- The "Global Cell Lysis & Disruption Market Size, Share & Trends Analysis Report by Application (Protein Isolation, Downstream Processing), by...

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.

/PRNewswire/ -- The "18th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to...

/PRNewswire/ -- The "18th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to...

Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.

From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.

Waters has announced a five-year investment to develop new analytical technology for bioprocessing and biomanufacturing with the University of Delaware.

Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.

The European Medicines Agency’s human medicines committee (CHMP) has approved two new additional manufacturing sites for Comirnaty in Italy.